RNS Number:9440P
Alizyme PLC
19 September 2003


Meetings today:


Alizyme will be holding an analyst meeting at 10.00 am at the offices of
Buchanan Communications, 107 Cheapside, London EC2V. If you would like to attend
please contact Lisa Baderoon, Rebecca Skye Dietrich or Charlie Forsyth on 020
7466 5000.

Please note, there will not be any other formal meetings but the Company will be
available for telephone interviews throughout the day. Please contact Lisa
Baderoon, Rebecca Skye Dietrich or Charlie Forsyth on 020 7466 5000 if you would
like to speak to the Company.

Immediate Release                                             19 September 2003



      ALIZYME ANNOUNCES SUCCESSFUL PRELIMINARY RESULTS FROM ITS PHASE IIb

                             OBESITY CLINICAL TRIAL


Cambridge UK, 19 September 2003: Alizyme plc (LSE:AZM) is pleased to announce
the successful preliminary results of its Phase IIb clinical trial in clinically
obese patients of ATL-962 for the treatment of obesity.


Highlights of the results:

* Primary endpoint met - statistically significant reduction in weight at all 
  doses

* Demonstration of efficacy comparable to other approved obesity drugs of the 
  same class

* No safety or tolerability issues

* Establishment of competitive product profile

* Allows for preparation for Phase III development

* Results suitable for continuing dialogue with potential global licensing 
  partners

The multi-centre clinical trial for ATL-962 enrolled 372 clinically obese
patients and was performed in specialist clinics in 5 European countries,
including the UK. It was a randomised, double-blind, placebo controlled,
parallel group trial comparing three doses of ATL-962 (60, 120 and 240mg three
times a day) with placebo, over three months. The objectives of the study were
to determine the effect of ATL-962 on weight loss, together with its safety and
tolerability profile, in clinically obese subjects having a BMI of 30 or
greater, or over 28 with other associated risk factors (see Editor's note).

The trial met its primary endpoint of weight loss across all three dose levels,
demonstrating a statistically significant reduction in weight (p